AP4B1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line, carrying a targeted disruption of the AP4B1 gene. AP4B1 encodes the beta subunit of the AP-4 adaptor protein complex, a clathrin-associated heterotetramer that mediates vesicular trafficking. This loss-of-function model, generated without clonal selection, offers a heterogeneous cell pool for studying AP-4-dependent processes in a lung epithelial context. The knockout population enables examination of cargo sorting and autophagy without the artefacts of single-clone selection.
A-549 cells are a hypotriploid human alveolar basal epithelial line derived from a 58-year-old male with lung carcinoma, exhibiting adherent epithelial morphology. Widely used in respiratory and cancer research, these cells provide a well-characterized platform for genetic manipulation to investigate oncogenic signaling, metastasis, and drug response. Their robust growth and defined genetic background facilitate studies of membrane trafficking and autophagy within a lung adenocarcinoma setting.
The AP4B1 protein, the beta subunit of the AP-4 adaptor complex, is responsible for sorting specific transmembrane cargo proteins from the trans-Golgi network (TGN) into endosomal compartments. The AP-4 complex includes AP4E1, AP4M1, and AP4S1, and interacts with clathrin and TGN46 to recognize cargo such as ATG9A and amyloid precursor protein (APP). AP4B1 transcription is activated by SP1 and modulated by cellular stress signals, and its function is essential for autophagic flux through ATG9A delivery to autophagosomes. Knockout of AP4B1 disrupts this trafficking, causing mislocalization of ATG9A and APP, impaired autophagy, and defective low-density lipoprotein receptor (LDLR) transport.
In A-549 lung adenocarcinoma cells, AP4B1 knockout provides a model to study the role of AP-4-mediated trafficking in cancer cell biology. While AP4B1 mutations are primarily linked to neurological disorders such as hereditary spastic paraplegia type 47 (SPG47), its disruption in a lung carcinoma context enables investigation of autophagy and cargo mislocalization in a non-neuronal, cancerous environment. This polyclonal knockout population is particularly suited for examining how impaired autophagic flux influences tumor cell proliferation, migration, and stress responses, and for screening compounds that may restore trafficking defects.
Typical applications include Western blot and RT-qPCR for knockout validation and analysis of downstream targets like ATG9A and APP; immunofluorescence to assess cargo mislocalization; co-immunoprecipitation of AP-4 complex components; autophagy flux measurements via LC3 turnover; and wound-healing migration assays. These cells are useful for drug testing targeting trafficking pathways and for modeling neurodevelopmental disorder mechanisms in a tractable cell line. For further technical details or ordering support, contact Ascent Research.
